Hydrophobic Interaction Chromatography Market Share

North American Market Forecast

 North America industry is predicted to dominate majority revenue share of 35% by 2037, impelled by growing cases of cancer and autoimmune diseases in the region. Growing cases of cancer and autoimmune diseases are driving the market growth. In 2022, the United States recorded around 1,918,030 new cancer cases and nearly 609,360 cancer deaths. Monoclonal antibodies are commonly utilized in cancer therapy. HIC allows for the production of high-purity mAB, which is employed in cancer therapy.

European Market Statistics

The European hydrophobic interaction chromatography market is estimated to be the second largest, registering a share of about 28% by the end of 2037. The presence of the leading biopharma companies leads to the higher discovery of therapies and results in higher demand for the HIC for better output of these drugs. Many of the world's biggest pharmaceutical companies have their base in Europe, including Novartis, Roche, Bayer, Novo Nordisk, AstraZeneca, Sanofi, GSK, and many others.